Non-Small Cell Lung Cancer (NSCLC) - Dynamic Market Forecast to 2025

Non-Small Cell Lung Cancer (NSCLC) - Dynamic Market Forecast to 2025


The NSCLC therapeutics market is a rapidly evolving field in which new developments are constantly influencing the landscape. The Forecast Update is designed to help clients stay abreast of the latest news in the NSCLC space, including regulatory, commercial, and clinical events, and to understand how these events will impact the market forecast.


Key events covered in the Dynamic Market Forecast include -

  • Regulatory filings
  • Approval decisions
  • Pricing changes
  • Patent litigation
  • Clinical trial data announcements
  • Clinical trial failures
  • Clinical trial timeline updates
Components of the slide deck include -
  • Timeline of market-impacting events
  • Key clinical trial landscape updates
  • Detailed analysis of the most impactful events, including new primary research to gain Key Opinion Leader perspective
  • Overview of updates to the forecast model based on anticipated future impact of events
  • Forward-looking events calendar listing expected key updates to the NSCLC competitive space in the next quarter
Reasons to buy
  • Recent regulatory events
  • Recent commercial events
  • Recent clinical events
  • Market dynamics in the frontline NSCLC setting
  • Landscape changes in the EGFR-mutant NSCLC setting
  • Projected treatment algorithm shifts in the ALK-mutant NSCLC setting

1. Dynamic Market Forecast Overview
1.1 Related Reports
1.2 Upcoming Related Reports
2. Executive Summary
2.1 Key Events in Update 9-
2.2 Updates to Treatment Algorithms
2.3 Clinical Trial Landscape Updates 12-
2.4 Pipeline Landscape Updates
2.5 Market Insight on Key Events
3. Event 1: Market Dynamics Shift in Frontline NSCLC
3.1 Key Updates to the Frontline Non-squamous Setting
3.2 Merck & Co., Keytruda (pembrolizumab) 18-
3.3 AstraZeneca, Imfinzi (durvalumab) + tremelimumab 20-
3.4 Pfizer and Merck KGaA , Bavencio (avelumab)
3.5 Roche, Tecentriq (atezolizumab)
3.6 Novartis, Tafinlar (dabrafenib) + Mekinist (trametinib)
3.7 Additional Clinical Trial Updates- Frontline Setting 25-
3.8 Summary/Trends
3.9 Sources
4. Event 2: Weak Competition in the EGFRm+ Segment Creates Opportunity for Tagrisso
4.1 Key Updates to the EGFRm+ Segment
4.2 AstraZeneca, Tagrisso (osimertinib) 31-
4.3 Pfizer, dacomitinib
4.4 Additional Clinical Trial Updates- EGFRm+ Setting
4.5 Summary/Trends
4.6 Sources
5. Event 3: New SOC Anticipated in the ALKm+ 1L Setting
5.1 Key Updates to the ALKm+ Setting
5.2 Roche, Alecensa (alectinib)
5.3 Takeda, Alunbrig (brigatinib)
5.4 Pfizer, lorlatinib
5.5 Summary/Trends
5.6 Sources
6. Other Events of Interest
6.1 Various Developers 46-
6.2 Sources
7. Dynamic Market Forecast Highlights
7.1 Updates to Frontline NSCLC Segment
7.2 Updates to EGFRm+ NSCLC Segment
7.3 Updates to ALKm+ NSCLC Segment
7.4 Selected Additional Forecast Updates
8. Events Calendar
8.1 Key Clinical Events Expected in Q4 2017 55-
9. Appendix
9.1 Methodology
9.2 Primary Research 59-
9.3 About the Authors 61-
9.4 About GlobalData
9.5 Contact Us
9.6 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook